{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-002033","form_type":"8-K","ticker":"CNSP","cik":"0001729427","company_name":"CNS Pharmaceuticals, Inc.","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.776582+00:00","generated_at":"2026-06-04T04:45:57.343838+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CNS Pharma FY2023 net loss $18.9M; Berubicin DSMB OK, enrollment done, topline due H1 2025","bullets":["Net loss $18.9M vs $15.3M in 2022; R&D expenses $14.1M (up from $9.3M) on Berubicin trial costs.","Cash at Dec 31, 2023 only $0.5M; subsequent $4.0M public offering extends runway into late Q2 2024.","Berubicin GBM study completed enrollment; DSMB recommended continue without modification after interim futility analysis.","Topline data from potentially pivotal Berubicin trial expected in first half 2025.","Appointed biotech commercialization leader Amy Mahery to Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-002033","json":"https://secwatch.observer/filing/0001683168-24-002033.json","markdown":"https://secwatch.observer/filing/0001683168-24-002033.md","text":"https://secwatch.observer/filing/0001683168-24-002033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824002033/0001683168-24-002033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824002033/cns_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:45:57.343838+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7b9501ae91ff026eb36b78cc92b526f2b04c569c","claim":"CNS Pharmaceuticals, Inc. reported the full year ended December 31, 2023 results: net income approximately $18.9 million.","evidence_excerpt":"The net loss for the year ended December 31, 2023 was approximately $18.9 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824002033/0001683168-24-002033-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2023"},{"label":"Net income","value":"approximately $18.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}